NCT05104788招募中2 期
A Phase II, Single-Arm, Prospective Study of Neoadjuvant Icotinib With Chemotherapy for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable for Stage II to IIIB(N2) Non-small Cell Lung Cancer
Peking University Cancer Hospital & Institute1 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2021年10月25日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- Major Pathological Response (MPR)
研究概览
简要总结
This is a Phase II, single-Arm, prospective study of neoadjuvant Icotinib with chemotherapy for the treatment of patients with epidermal growth factor receptor mutation positive, resectable for stage II to IIIB(N2) Non-small Cell Lung Cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
- •Male or female, at least 18 years of age.
- •Histologically or cytologically documented lung adenocarcinoma within 60 days prior to study enrollment.
- •Clinical stage IIA/IIB/IIIA/IIIB assessed by EBUS-TBNA or PET(positron emission tomography)/CT can be resected.
- •EGFR mutation was detected by Amplification Refractory Mutation System(ARMS) and confirmed to be one of the 2 common EGFR mutations known to be associated with EGFR-TKI （epidermal growth factor receptor tyrosine kinase inhibitors）sensitivity (Ex19del, L858R).
- •Presence of at least one accurately measurable lesion, CT showing a maximum diameter of 10mm at baseline (except for lymph nodes with a short axis of 15mm required) and suitable for accurate repeat measurements.
- •Eastern Cooperative Oncology Group (ECOG) performance status （PS） of 0 or 1 at enrolment.
- •Hematology , liver and kidney function are adequate for neoadjuvant therapy.
- •Cardiopulmonary function suitable for surgical treatment (ECG, echocardiography, pulmonary function or blood gas analysis).
- •Serum pregnancy test (for females of childbearing potential) negative at screening.Female patients of non-childbearing potential must meet at least 1 of the following criteria:
- •① Achieved postmenopausal status, defined as follows: cessation of regular menses forat least 12 consecutive months with no alternative pathological or physiological cause; status may be confirmed with a serum follicle- stimulating hormone (FSH)level confirming the postmenopausal state;
- •② Have undergone a documented hysterectomy and/or bilateral oophorectomy;
- •③ Have medically confirmed ovarian failure. All other female patients (including female patients with tubal ligations） are considered to be of childbearing potential.
- •Male subjects must be willing to use barrier contraception
排除标准
- •Mixed squamous cell carcinoma, large cell carcinoma，small cell lung cancer.
- •Prior treatment with any systemic anti-cancer therapy for NSCLC including chemotherapy, biologic therapy, immunotherapy, or any investigational drug.
- •Pregnant female patients; breastfeeding female patients.
- •Current use of (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of Cytochrome P450 3A4(CYP3A4)(at least 3 weeks prior).
- •Evidence of any severe or uncontrolled systemic disease, including uncontrolled hypertension and active bleeding, that the investigator considers to be detrimental to patient participation in the study or to adherence to the protocol. Active and clinically significant bacterial, fungal, or viral infection including hepatitis B virus (HBV) or hepatitis C virus (HCV) (e.g., in case of known HBsAg or HCV antibody positivity), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS)-related illness.
- •Clinically significant cardiovascular disease, that is, active or within 3 months prior to enrollment: cerebral vascular accident/stroke, myocardial infarction, unstable angina,congestive heart failure (New York Heart Association Classification Class ≥ II), second-degree or third-degree Atrioventricular（AV）block (unless paced) or any AV block with PR >220 msec; or ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥ 2, uncontrolled atrial fibrillation of any grade, bradycardia defined as <50 bpm (unless patient is otherwise healthy such as long-distance runners, etc.), machine-read ECG with QTc(corrected QT interval) >470 msec, or congenital long QT syndrome.
- •A history of hypersensitivity to Icotinib with or without active excipients or to drugs of similar chemical structure or class, and uncontrollable nausea and vomiting, chronic gastrointestinal disease, inability to swallow formulated drugs, or having undergone major bowel resection that would interfere with adequate absorption of Icotinib.
- •Past medical history of Interstitial lung disease（ ILD）, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
- •Inadequate bone marrow reserve (a leukocyte count less than 4000 mm3, a platelet count less than 100,000 mm3, and a hemoglobin level less than 10 g/dL); adequate renal function deficiency(not normal serum creatinine and blood urea nitrogen levels, and a creatinine clearance level 60 mg/minute); and an inadequate serum aspartate aminotransferase level more than 2.5 times the upper normal limit (UNL) and a serum alanine aminotransferase level more than 2.5 times the UNL.
研究组 & 干预措施
Icotinib with platinum-based chemotherapy
Experimental
Icotinib 125 mg TID plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
干预措施: Icotinib (Drug)
Icotinib with platinum-based chemotherapy
Experimental
Icotinib 125 mg TID plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
干预措施: Cisplatin (Drug)
Icotinib with platinum-based chemotherapy
Experimental
Icotinib 125 mg TID plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
干预措施: Carboplatin (Drug)
Icotinib with platinum-based chemotherapy
Experimental
Icotinib 125 mg TID plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
干预措施: Pemetrexed (Drug)
结局指标
主要结局
Major Pathological Response (MPR)
时间窗: From date of randomization to an average of 12 weeks after the first dose
Defined as ≤10% residual cancer cells in the main tumour, as assessed per central pathology laboratory post-surgery
次要结局
- Pathological complete response (pCR)(From date of randomization to an average of 12 weeks after the first dose)
- Overall Survival (OS)(Up to approximately 5.5 years after the last patient is randomized)
- Disease free survival (DFS)(From date of randomization up to approximately 42 months after date of resection)
- Objective response rate(ORR)(Baseline (Prior to surgery))
- Disease control rate(DCR)(Baseline (Prior to surgery))
- R0 surgical resection rate(Post surgery (within one week))
- Incidence of Adverse Events(From the time of enrollment to either 28-days after the last dose of last study treatment for patients who do not undergo surgery, or 90-days post-surgery)
研究者
Wu Nan
Principal Investigator
Peking University Cancer Hospital & Institute
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous CellPFSNCT04520035Fudan University60
已完成
不适用
Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal AdenocarcinomaGastric CancerNCT05540145Cancer Institute and Hospital, Chinese Academy of Medical Sciences70
撤回
2 期
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast CancerBreast CancerNCT02215876Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
进行中（未招募）
2 期
Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label TrialHER2-low-expressing Breast CancerHormone Receptor-positive Breast CancerNeoadjuvant TherapyBreast CancerNCT05165225Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University48
招募中
2 期
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk FeaturesNon-small Cell Lung Cancer Stage IIINCT06449313Georgetown University21